ATAP News

The Alliance for Transparent & Affordable Prescriptions (ATAP) is encouraged by UnitedHealthcare’s announcement that it will start passing on savings from drug manufacturers directly to patients by applying manufacturer rebates and discounts to their medication costs at the point of sale.

The Alliance for Transparent & Affordable Prescriptions (ATAP) applauds the White House for recognizing the increasingly harmful role of pharmacy benefit managers (PBMs) in the prescription drug market in a report released Friday outlining policy options to reduce drug prices and encourage medical innovation.

The Alliance for Transparent & Affordable Prescriptions (ATAP) is encouraged by President Trump’s statement during the State of the Union address last night that reducing prescription drug prices is one of his “greatest priorities.”

ATAP urges CMS to adopt a policy requiring sponsors to include all price concessions at the point of sale for Medicare beneficiaries. 

We thank the Subcommittee for scheduling today’s hearing entitled “Examining the Drug Supply Chain.” ATAP was formed on a shared concern that PBMs play an increasingly harmful role in our supply chain.

In a letter submitted to the Centers for Medicare and Medicaid Services (CMS), the Alliance for Transparent and Affordable Prescriptions (ATAP) urged the agency to address the increasingly harmful role of pharmacy benefit managers (PBMs) in the prescription drug delivery system.   

We urge Congress to encourage CMS to adopt a policy requiring sponsors to include price concessions at the point of sale for Medicare beneficiaries.